A síndrome de Legg-Calvé-Perthes ou doença de Perthes é uma doença degenerativa da articulação da anca (quadril em português brasileiro) em que ocorre. El absceso del psoas es una enfermedad infrecuente en niños. Puede tener una en pediatría es primario; sin embargo, en ocasiones, puede ser de origen secundario y médula espinal, enfermedad de. Legg-Calvé-Perthes, entre otros Download Citation on ResearchGate | Enfermedad de Legg Calvé Perthes (LCP) en varios aspectos de la enfermedad de Legg Calvé Perthes y la evolución de caderas de August · Anales espanoles de pediatria.
|Published (Last):||2 July 2018|
|PDF File Size:||9.24 Mb|
|ePub File Size:||14.82 Mb|
|Price:||Free* [*Free Regsitration Required]|
It has been suggested that the cause of Perthes diseasemay be intravascular thrombosis induced by a potentialcongenital hemostatic perthfs leading to conditions ofthrombophilia or hyperfibrinolysis.
Complete study of hemostasis with coagulation and antithrombinfactors as well as study of thrombophilia andfibrinolysis in these patients could determine the prevalenceof hemostasis and fibrinolysis in this group of patients. Alterations in hemostasis and thrombosis were detectedin one patient prethes had moderate-to-light protein Sdeficiency.
The remaining patients were considered withinthe normal range when age was taken into account.
Síndrome de Legg-Calvé-Perthes
Epidemiological and laboratory data from this group ofpediatric patients and from the control group do not supportthe hypothesis that a thrombogenesis defect couldbe the underlying cause of avascular necrosis of the hipjoint. Aguirre Canyadell aI. Background It has been suggested that the cause of Perthes diseasemay be intravascular thrombosis induced by a potentialcongenital hemostatic disorder leading to conditions ofthrombophilia or hyperfibrinolysis.
Patients and method Complete study of hemostasis with coagulation and antithrombinfactors as well as study of thrombophilia andfibrinolysis in these patients could determine the prevalenceof hemostasis and fibrinolysis in this group of patients. Results Alterations in hemostasis and thrombosis were detectedin one patient who had moderate-to-light protein Sdeficiency. The remaining patients were considered withinthe normal range when age was enfeermedad into account. Conclusions Epidemiological and laboratory data from this group ofpediatric patients and from the control group pediatgia not supportthe hypothesis that a thrombogenesis defect couldbe the underlying cause of oerthes necrosis of the hipjoint.
Enfermedad de Legg-Calve-Perthes | HCA Healthcare
Disorders of hemostasis in childhood: Thromb Haemost, 78pp. Resistance to activated protein C and Legg-Perthes disease. Clin Orthop,pp. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature,pp. Genetics aspects of Perthes disease: Variability of thrombosis among homozigous siblings with resistance to activated protein C due to an Arg-Gln mutaion in gen for factor V.
J Med,pp. Anticoagulant protein C pathway defective in majority of thromboembolic patients. Blood, 82pp. N Engl J Med,pp. Activated protein C resistance as an additional risk factor for thrombosis in protein C deficient families. Blood, 84pp. Mutation in gene coding for factor V and the risk of myocardial infarction, stroke and venous thrombosis in apparently healthy men.
High risk of thrombosis in patients homozigous for factor V Leiden activated protein C resistance. Blood, 85pp. J Biol Chem,pp. Association of idiopathic venous thromboembolism with single point-mutation at Arg of factor. Lancet,pp. Identification of the same factor V gene mutation in 47 of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest, 94pp. Non traumatic osteonecrosis of the femoral head: Relation of altered hemostasis to etiology. Am J Hematol, 45pp.
Idiopathic osteonecrosis, hypofibrinolysis, high plasminogen activator inhibitor, high Lp aand therapy with stanozolol. Am J Hematol, 48pp.
Clin Othop,pp. Pathophysiology of osteonecrosis of the jaw: J Lab Clin Med,pp. Severe thrombotic disease in a young man with bone marrow and skeletal changes and with a high content of an inhibitor in the fibrinolytic system.
Acta Med Scand,pp. Decreased fibrynolitic potential in patients with idio-pathic avascular necrosis and transient osteoporosis of the hip. Am J Hematol, 44pp. Changes in coagulation-fibrinolysis system in Legg-Perthes disease: Association of antithrombotic factor deficiencies and hy-pofibrinolysis with Legg-Perthes disease.
Protein C and S deficiency, thrombofilia and hypofibrinolysis: Pediatr Res, 35pp. Thromb Haemost, 69pp. Familial idiopathic oeteonecrosis mediated by familial hypofibrinolysis witn enfermevad levels of plasminogen activator inhibitor.
Thromb Haemost, 71pp. Familial hypofibrinolysis and venous thrombosis. Br J Hematol, 71pp.
J Pediatr Orthop, 19pp. Blood, 87pp. Perthes’ disease and the relevance of thrombophilia. Maturation of the hemostatic system during childhood.
Blood, 80pp. Special laboratory evaluation of coagulation. Antithrombin heparin cofactor assay with new chromogenic substrates. Thromb Res, 11pp.
Enfermedad de Legg-Calve-Perthes
Espectrophotometric solid-phase tissue plasminogen activator activity assay Sofia-tPA for high-fibrin-affinity tissue plasminogen activators. Anal Biochem,pp. Determination of plasminogen activator and its fast inhibitor in plasma. Clin Chem, 32pp. Blood collection peiatria strongly acid citrate anticoagulant used in a study of dietary influence of basal Tpa activity.
Thromb Haemost, 62pp.
The second international anticardiolipin standardization workshop. The Kinston antiphospholipid group. Am J Clin Pathol, 94pp. Necesidades del alumnado con diabetes tipo 1 en Si continua navegando, consideramos que acepta su uso. To improve our services and products, we use “cookies” own or third parties authorized to show advertising related to client preferences through the pwrthes of navigation customer behavior.
Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Are you a health professional able to prescribe or dispense drugs?